See more : Taylor Wimpey plc (TWODF) Income Statement Analysis – Financial Results
Complete financial analysis of Milestone Pharmaceuticals Inc. (MIST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Milestone Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Wilton Makmur indonesia Tbk. (SQMI.JK) Income Statement Analysis – Financial Results
- Tata Steel Limited (TATASTEEL.BO) Income Statement Analysis – Financial Results
- Sun Cheong Creative Development Holdings Limited (1781.HK) Income Statement Analysis – Financial Results
- SC Engineering Co., Ltd (023960.KS) Income Statement Analysis – Financial Results
- Signature Bank of Georgia (SGBG) Income Statement Analysis – Financial Results
Milestone Pharmaceuticals Inc. (MIST)
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.00M | 5.00M | 15.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 480.00K | 0.00 | 376.00K | 236.00K | 10.00K | 8.00K |
| Gross Profit | 1.00M | 4.52M | 15.00M | -376.00K | -236.00K | -10.00K | -8.00K |
| Gross Profit Ratio | 100.00% | 90.40% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.05M | 39.83M | 38.67M | 34.49M | 41.99M | 16.85M | 5.64M |
| General & Administrative | 15.93M | 15.72M | 12.40M | 10.29M | 7.00M | 3.05M | 1.50M |
| Selling & Marketing | 15.11M | 9.10M | 7.00M | 5.94M | 8.89M | 3.92M | 1.13M |
| SG&A | 31.05M | 24.81M | 19.40M | 16.22M | 15.90M | 6.97M | 2.63M |
| Other Expenses | 0.00 | 0.00 | 7.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 62.10M | 64.64M | 58.07M | 50.71M | 57.88M | 23.82M | 8.27M |
| Cost & Expenses | 62.10M | 64.64M | 58.07M | 50.71M | 57.88M | 23.82M | 8.27M |
| Interest Income | 3.97M | 1.25M | 220.00K | 726.00K | 2.60M | 711.00K | 186.00K |
| Interest Expense | 2.55M | 0.00 | 0.00 | 726.00K | 2.60M | 0.00 | 0.00 |
| Depreciation & Amortization | 92.00K | 480.00K | 362.00K | 376.00K | 236.00K | 10.00K | 8.00K |
| EBITDA | -56.85M | -58.36M | -42.98M | -50.71M | -57.88M | -23.36M | -8.26M |
| EBITDA Ratio | -5,684.50% | -1,192.84% | -286.53% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -61.10M | -59.64M | -43.07M | -50.71M | -57.88M | -23.82M | -8.27M |
| Operating Income Ratio | -6,109.80% | -1,192.84% | -287.15% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.41M | 1.25M | 220.00K | 726.00K | 2.60M | 711.00K | 186.00K |
| Income Before Tax | -59.69M | -58.39M | -42.85M | -49.98M | -55.29M | -23.11M | -8.08M |
| Income Before Tax Ratio | -5,968.50% | -1,167.76% | -285.69% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.25M | -220.00K | -17.00K | -56.00K | 74.00K | 4.00K |
| Net Income | -59.69M | -57.13M | -42.63M | -49.97M | -55.23M | -23.19M | -8.09M |
| Net Income Ratio | -5,968.50% | -1,142.68% | -284.22% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.39 | -1.35 | -1.02 | -1.70 | -3.50 | -0.98 | -0.34 |
| EPS Diluted | -1.39 | -1.35 | -1.02 | -1.70 | -3.50 | -0.98 | -0.34 |
| Weighted Avg Shares Out | 42.96M | 42.45M | 41.83M | 29.34M | 15.78M | 23.65M | 23.65M |
| Weighted Avg Shares Out (Dil) | 42.96M | 42.45M | 41.83M | 29.34M | 15.78M | 23.65M | 23.65M |
Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update
MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2021 and provided a clinical, regulatory, and...
Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China
MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals (Ji Xing) to develop...
Milestone Pharmaceuticals Stock Is a Bet On Etripamil
If Milestone Pharmaceuticals' Etripamil nasal spray succeeds in clinical trials, MIST stock is going to see big growth. The post Milestone Pharmaceuticals Stock Is a Bet On Etripamil appeared first on InvestorPlace.
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a clinical...
Milestone Pharmaceuticals Announces First Patient Enrolled in the ReVeRA Study, its Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate
MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the first patient has been enrolled in its Phase 2 proof-of-concept study of etripamil nasal...
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., Nov. 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief...
Milestone Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., Nov. 13, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended...
Now Hear This: New music from AJ Tracey, MIST, Kehlani, Big Thief and Tora
In her weekly column, our music correspondent goes through the best new releases
LLY, OXM, AMAG, MIST and CPIX as Zacks Bull and Bear of the Day
LLY, OXM, AMAG, MIST and CPIX as Zacks Bull and Bear of the Day
3 Drugmakers Still Worth Betting on Amid Coronavirus Woes
Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.
Source: https://incomestatements.info
Category: Stock Reports